INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Esperion Therapeutics, Inc. of Class Action Lawsuit & a Lead P...
February 26 2016 - 2:00PM
Business Wire
The following statement is being issued by Levi & Korsinsky,
LLP:
To: All persons or entities who purchased or otherwise
acquired securities of Esperion Therapeutics, Inc.
(“Esperion”) (NASDAQ: ESPR) between August
18, 2015 and September 28, 2015.
You are hereby notified that a securities class action
lawsuit has been commenced in the USDC for the Eastern District of
Michigan. To get more information go to:
http://zlk.9nl.com/esperion-espr.
The complaint alleges that Defendants issued false and
misleading statements regarding the Company’s business and
prospects, including that there was no clear path to approval for
ETC-1002, the Company’s lead product candidate designed to lower
LDL-cholesterol levels, and that the FDA had encouraged the Company
to initiate a cardiovascular outcomes trial (“CVOT”) and that
completion of a CVOT could be necessary prior to approval of
ETC-1002.
On August 17, 2015, Esperion reported to investors material
events from an August 2015 meeting with the FDA; the Company stated
that during the meeting it was informed by the FDA that the Company
would not have to complete a CVOT to gain approval of ETC-1002.
Then in a September 28, 2015 news release the Company noted that
the FDA had actually “encouraged the Company to initiate a
cardiovascular outcomes trial promptly” and it may be necessary to
have a completed CVOT prior to approval.
If you suffered a loss in Esperion you have until
March 14, 2016 to request that the
Court appoint you as lead plaintiff. Your ability to share in any
recovery doesn’t require that you serve as a lead plaintiff. To
obtain additional information, contact Joseph E. Levi, Esq. either
via email at jlevi@zlk.com or by telephone at (212) 363-7500,
toll-free: (877) 363-5972, or visit
http://zlk.9nl.com/esperion-espr.
Levi & Korsinsky is a national firm with offices in New
York, New Jersey, California, Connecticut, and Washington D.C. The
firm’s attorneys have extensive expertise and experience
representing investors in securities litigation involving financial
fraud, and have recovered hundreds of millions of dollars for
aggrieved shareholders. Attorney advertising. Prior results do not
guarantee similar outcomes.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160226005747/en/
Levi & Korsinsky, LLPEduard Korsinsky, Esq.Tel:
212-363-7500Toll Free: 877-363-5972Fax: 212-363-7171www.zlk.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024